Abstract:The Raf-MEK-ERK pathway is commonly activated in human cancers, largely attributable to the extracellular signal-regulated kinases (ERKs) being a common downstream target of growth factor receptors, Ras, and Raf. Elevation of these up-stream signals occurs frequently in a variety of malignancies and ERK kinases play critical roles in promoting cell proliferation. Therefore, inhibition of MEK-mediated ERK activation is very appealing in cancer therapy. Consequently, numerous MEK inhibitors have been developed over the years. However, clinical trials have yet to produce overwhelming support for using MEK inhibitors in cancer therapy. Although complex reasons may have contributed to this outcome, an alternative possibility is that the MEK-ERK pathway may not solely provide proliferation signals to malignancies, the central scientific rationale in developing MEK inhibitors for cancer therapy. Recent developments may support this alternative possibility. Accumulating evidence now demonstrated that the MEK-ERK pathway contributes to the proper execution of cellular DNA damage response (DDR), a major pathway of tumor suppression. During DDR, the MEK-ERK pathway is commonly activated, which facilitates the proper activation of DDR checkpoints to prevent cell division. Inhibition of MEK-mediated ERK activation, therefore, compromises checkpoint activation. As a result, cells may continue to proliferate in the presence of DNA lesions, leading to the accumulation of mutations and thereby promoting tumorigenesis. Alternatively, reduction in checkpoint activation may prevent efficient repair of DNA damages, which may cause apoptosis or cell catastrophe, thereby enhancing chemotherapy's efficacy. This review summarizes our current understanding of the participation of the ERK kinases in DDR.

Roles of Eef-2 Kinase in Cancer.

Eef2k As an Important Kinase Associated with Cancer Survival and Prognosis

Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer

Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer

Eukaryotic Elongation Factor 2 Kinase and Cancer

What is the impact of eukaryotic elongation factor 2 kinase on cancer: A systematic review

Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy

Oncogenic activation of EEF1A2 expression: a journey from a putative to an established oncogene

The Eef1a Protein in Cancer: Clinical Significance, Oncogenic Mechanisms, and Targeted Therapeutic Strategies

The eEF2 kinase-induced STAT3 inactivation inhibits lung cancer cell proliferation by phosphorylation of PKM2

Translational Regulator Eif2α in Tumor

Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells

Insights Into the Pathologic Roles and Regulation of Eukaryotic Elongation Factor-2 Kinase

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

The Roles of EphB2 in Cancer

Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer

Elongation factor eEF2 kinase and autophagy jointly promote survival of cancer cells

Regulation and Functional Role of Eef1a2 in Pancreatic Carcinoma.

The Role of the Eph Receptor Family in Tumorigenesis

Elongation factor 2 kinase promotes cell survival by inhibiting protein synthesis without inducing autophagy

A comprehensive review on the dynamics of protein kinase CK2 in cancer development and optimizing therapeutic strategies